DSIP Dosage: Cognitive Research Protocol

Read this first

Dosage and protocol figures on this page are reproduced only from the matching PeptideDosages.com protocol. The 3 ml table is arithmetic based on those source amounts and the listed vial sizes. Educational research only — not instructions or medical advice.

Dosage chart

The dosage amounts and schedules below come only from PeptideDosages.com. Syringe-unit figures are mathematical conversions of those source amounts using exactly 3 ml of bacteriostatic water. Educational reference only — not instructions or medical advice.

DSIP · 10 mg Vial

DSIP (Delta Sleep-Inducing Peptide) is dosed at 100 mcg–300 mcg daily via subcutaneous injection in educational protocols, usually before bedtime.

Typical daily range: 100–300 mcg once daily in the evening (gradual titration).

Standard / Gradual Approach

Week	Daily Dose (mcg)
Week 1	100 mcg
Week 2	150 mcg
Week 3	200 mcg
Weeks 4–8	250–300 mcg

3 ml conversion

Select vial strength

5 mg + 3 ml = 1.67 mg/ml. Choose your vial strength to update the units below.

Source dose	U-100 syringe
100 mcg	6.0 units
150 mcg	9.0 units
200 mcg	12 units
300 mcg	18 units

Source chart on peptidedosages.com

Other cognitive compounds

PE-22-28Spadin analogue, TREK-1 channel blocker PinealonSynthetic tripeptide (Glu-Asp-Arg) bioregulator SelankTuftsin analogue heptapeptide SemaxACTH(4-10) analogue heptapeptide Semax + SelankACTH(4-10) analogue + tuftsin analogue blend CerebrolysinPorcine brain-derived peptide preparation

All research protocols

DSIP: research background

What the compound is

Delta sleep-inducing peptide (DSIP) is a nonapeptide, meaning it consists of nine amino acids, with a molecular weight of 849. It was first isolated in 1977 from rabbit cerebral venous blood (PMID 16539679, PMID 6145137). DSIP's structure is distinct from other known peptide families (PMID 16539679). DSIP-like material has been found in the brain and peripheral organs of rats, and in the plasma of several mammals (PMID 6145137). In humans, DSIP-like immunoreactivity (DSIP-LI) is present in gut endocrine cells (PMID 2664725).

How it is thought to work

DSIP is described as a recovery-enhancing agent that targets circadian and mitochondrial regulators (PMID 41490200). A possible mechanism of action suggested for DSIP involves the modulation of adrenergic transmission (PMID 3550726). One abstract hypothesizes that DSIP or DSIP-like peptides may activate hypothalamic neural circuitry responsible for stimulating luteinizing hormone (LH) release, which is reported to occur during sleep (PMID 3550343).

What laboratory and animal studies report

In intact rats, exogenous DSIP (12 µg/100 g, i.p.) decreased lipid peroxidation products in liver and brain tissues. When administered before cold stress in rats, DSIP led to decreases in xanthine oxidase activity and lipid peroxidation products in the liver and brain (PMID 11265821). DSIP was also found to stimulate LH release in steroid-primed ovariectomized rats when administered intraventricularly (2 or 10 µg; 15 or 30 µg), but it had no direct effect on LH release from hemipituitaries in vitro (PMID 3550343). In rabbits, rats, and mice, DSIP was observed to induce mainly delta-sleep, while in cats, the effect on REM sleep was more pronounced (PMID 6145137).

Human evidence so far

DSIP has been shown to induce delta-sleep in humans (PMID 6145137). In the human gut, DSIP-like immunoreactivity (DSIP-LI) was found to be the richest source, located in gastrin/CCK, secretin, and PYY/glicentin cells (PMID 2664725). The gene encoding a protein sometimes called the 'delta sleep-inducing peptide immunoreactor' (also known as glucocorticoid-induced leucine zipper, GILZ) has been identified with oscillatory expression in human adipose tissue (PMID 19849801).

Open questions and limitations

The natural occurrence and biological activity of DSIP remain obscure (PMID 16539679). Although DSIP was initially regarded as a sleep-promoting factor, the link between DSIP and sleep has never been fully characterized, partly due to the lack of isolation of a DSIP gene, protein, or specific receptor (PMID 16539679). Some sleep-promoting effects observed in rabbits and rats were specifically linked to artificial DSIP structural analogues, not DSIP itself (PMID 16539679). While preclinical studies are promising, there is a current lack of clinical trials for therapeutic peptides like DSIP in orthopaedics (PMID 41490200).

Studies cited in this section

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews, 2026 (PMID 41490200)
Delta sleep-inducing peptide (DSIP): a still unresolved riddle. — Journal of neurochemistry, 2006 (PMID 16539679)
Delta-sleep-inducing peptide (DSIP): an update. — Peptides, 1986 (PMID 3550726)
Delta-sleep-inducing peptide (DSIP): a review. — Neuroscience and biobehavioral reviews, 1984 (PMID 6145137)
Delta sleep-inducing peptide (DSIP)-like immunoreactivity in gut: coexistence with known peptide hormones. — Peptides, 1989 (PMID 2664725)
Delta sleep-inducing peptide and glucocorticoid-induced leucine zipper: potential links between circadian mechanisms and obesity? — Obesity reviews : an official journal of the International Association for the Study of Obesity, 2009 (PMID 19849801)
The effects of delta sleep-inducing peptide on the intensity of lipid peroxidation and xanthine oxidase activity in rat tissues during cold stress. — Neuroscience and behavioral physiology, 2001 (PMID 11265821)
Delta sleep-inducing peptide (DSIP) stimulates LH release in steroid-primed ovariectomized rats. — Life sciences, 1987 (PMID 3550343)

Summarised from the PubMed abstracts listed above. Educational reference only — not medical advice or instructions.

Nearby in the protocol A–Z

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.

DSIP dosage protocol